Press releases

These press releases are intended for business journalists and analysts/investors

FDA Approves GlaxoSmithKline’s four-strain seasonal influenza vaccine for use in the US

GlaxoSmithKline plc announced today that the U.S. Food and Drug Administration (FDA) has approved FLUARIX® QUADRIVALENT (Influenza Virus Vaccine) for the immunisation of children (three years and older) and adults to help prevent disease caused by seasonal influenza (flu) virus subtypes A and type B contained in the vaccine.

Read more - FDA Approves GlaxoSmithKline’s four-strain seasonal influenza vaccine for use in the US Read more

GSK announces agreement in principle to increase its stake in GlaxoSmithKline Consumer Nigeria PLC

GlaxoSmithKline plc (“GSK”) (LSE: GSK) and GlaxoSmithKline Consumer Nigeria PLC (“GSK Nigeria” or the “Company”) today announced that they have reached agreement in principle on the terms of a proposal whereby GSK would increase its ownership in the Company from 46.4% to 80% (the “Proposal”).

Read more - GSK announces agreement in principle to increase its stake in GlaxoSmithKline Consumer Nigeria PLC Read more

GlaxoSmithKline and Human Genome Sciences announce FDA approval of Benlysta® (belimumab) for the treatment of systemic lupus erythematosus

GlaxoSmithKline plc (GSK) and Human Genome Sciences, Inc. (Nasdaq: HGSI) today announced that the U.S. Food and Drug Administration (FDA) has approved Benlysta® (belimumab) for the treatment of adult patients with active, autoantibody-positive systemic lupus erythematosus (SLE) who are receiving standard therapy.

Read more - GlaxoSmithKline and Human Genome Sciences announce FDA approval of Benlysta® (belimumab) for the treatment of systemic lupus erythematosus Read more